News

The beauty products leader's profit growth plan is working.

Target's new investments are paying off as the retailer returns to steady growth.

The prediction market operator is seeking CFTC approval for a copper perpetual as it moves further into traditional derivatives markets.

Tranches vest for each $500 million of custom product revenue through fiscal 2033

The company's cloud computing investments are starting to pay off.

Chevron isn't an exciting stock, but it delivers dependable returns.

Elon Musk's space company has taken shareholders on a wild ride in its first few months on the public market.

Tempus AI wrote a $1.5 billion check for a genomics company most investors had never heard of, and one blockbuster clinical trial announcement just changed everything about how that deal looks.

The stock is likely heading below $30.

The performance gap could reshape AI infrastructure economics

Here are Cathie Wood’s latest moves.

Tilray surged Wednesday alongside Canopy Growth and Aurora Cannabis, but one number from 2026 tells a very different story about why today's rally leaves the real problem untouched.

A top equity strategist is steering clients away from the S&P 500, and the reasoning goes deeper than simple valuation math. The real story is a balance-sheet wound that quietly healed while most investors were looking elsewhere.

Berkshire added to its position in Alphabet last quarter, and now has two iconic tech companies among its top-three holdings.

Palantir Stock Rises as Fresh AI Demand Keeps Post-Earnings Momentum Alive

A $100 million buyback authorization from United States Antimony landed just days after a badly missed quarter and a guidance cut that nearly halved the full-year outlook, raising a pointed question about whether management is signaling confidence or buying time.

Nelson Peltz is circling Wendy's with a take-private consortium even as the burger chain logs its sixth straight quarter of falling sales and shutters hundreds of restaurants. Whether deal fever or a genuine turnaround is driving this stock surge is the question every investor needs to answer before acting.

While rivals commit hundreds of billions to AI infrastructure, Apple's restrained capital approach has made its stock a hedge against volatility

Management is deploying record AI cash flow after the stock nearly halved from June's peak.

Enterprise Products Partners has proven to be a very bankable income investment over the long term.

Agency mortgage REITs promise fat monthly checks backed by government-guaranteed bonds, but leverage cuts both ways and dividend histories here are brutal. Three names keep pulling income investors back despite the scars.

Gold is up. So is Kinross.

OpenAI, Anthropic, Meta, and AWS are all competing for the same scarce silicon, and one chipmaker sits at the center of every deal. Whether that position justifies the current price depends on a set of risk factors most investors have not priced in.

Tesla's stock is on track for its worst performance since 2022, but back then, the markets as a whole were struggling.

Most stocks rose Wednesday, but a few big tech names told a different story. Here's what split the market again.

The treatment combines an mRNA shot with Merck's Keytruda.

The smartest move is to simply do nothing.

During the second quarter, Berkshire became a net buyer of stocks for the first time in over three years.

As usual, Warren Buffett said it best.

Lee Ainslie just torched Maverick Capital's playbook, dumping chip giants to pour hundreds of millions into five names that look nothing like his fund's typical bets, and one of them involves derivatives on a Brazilian fintech.